These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 11840225)

  • 1. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.